0001209191-23-010061.txt : 20230216 0001209191-23-010061.hdr.sgml : 20230216 20230216161826 ACCESSION NUMBER: 0001209191-23-010061 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230214 FILED AS OF DATE: 20230216 DATE AS OF CHANGE: 20230216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tatsis Ourania CENTRAL INDEX KEY: 0001789815 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 23638732 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS, INC. STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-14 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001789815 Tatsis Ourania C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Chief Reg. & Quality Off. Common Stock 2023-02-14 4 S 0 71 295.89 D 65694 D Common Stock 2023-02-14 4 S 0 20 296.48 D 65674 D Common Stock 2023-02-14 4 S 0 43 297.98 D 65631 D Common Stock 2023-02-14 4 S 0 135 299.60 D 65496 D Common Stock 2023-02-14 4 S 0 51 300.58 D 65445 D Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.36 to $296.32). Open market sales reported on this line occurred at a weighted average price of $297.98 (range $297.50 to $298.48). Open market sales reported on this line occurred at a weighted average price of $299.60 (range $299.19 to $300.16). Open market sales reported on this line occurred at a weighted average price of $300.58 (range $300.34 to $301.01). /s/ Christiana Stevenson, Attorney-in-Fact 2023-02-16